Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475948 | 0.95 | KMT2A (0.62) | KMT2ALMNAMAPTTP53THRB | |
| SCHEMBL6484083 | 0.94 | KMT2A (0.62) | KMT2ALMNAMAPT | |
| SCHEMBL3370380 | 0.91 | KMT2A (0.54) | KMT2ALMNAMAPT | |
| SCHEMBL6023129 | 0.88 | BCHE (0.54) | KMT2ALMNAPOLB | |
| SCHEMBL6476553 | 0.87 | KMT2A (0.55) | KMT2ALMNAMAPT | |
| SCHEMBL6023779 | 0.86 | KMT2A (0.51) | KMT2AGAA | |
| SCHEMBL6023108 | 0.85 | CA1 (0.54) | KMT2ALMNA | |
| SCHEMBL6023639 | 0.85 | — | — | |
| SCHEMBL6022541 | 0.85 | CA1 (0.57) | KMT2ALMNAGAA | |
| SCHEMBL6023518 | 0.84 | KMT2A (0.55) | KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930114-B2 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040138249-A1 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-07-15 | — | — | US | disclosed |
| EP-1347973-A1 | PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002048144-A1 | PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138249-A1 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | PDE7B, PDE2A, PDE5A | KMT2A 1344/4885LMNA 3598/4885MAPT 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.